75443-99-1
75443-99-1 結(jié)構(gòu)式
基本信息
阿柔比星鹽酸鹽
Aclarubicin HCl
Aclarubicin hydrochlride
ACLARUBICIN HYDROCHLORIDE
aclacinomycinahydrochloride
ACLARUBICIN HYDROCHLORIDE USP/EP/BP
syl)oxy)-2,5,7-trihydroxy-,methylester,hydrochloride,(1r-(1-alpha,2-beta,4
n-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyrano
1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-l-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-l-lyxo
1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-α-L-lyxo-hexopyranosyl]-3-(dimethylamino)-α-L-lyxo-hexopyranosyl]oxy]-, meth
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2023/01/06 | HY-N2306A | 鹽酸阿柔比星 Aclacinomycin A hydrochloride | 75443-99-1 | 5mg | 2800元 |
| 2023/01/06 | HY-N2306A | 鹽酸阿柔比星 Aclacinomycin A hydrochloride | 75443-99-1 | 10 mM * 1 mLin DMSO | 4479元 |
| 2023/01/06 | HY-N2306A | 鹽酸阿柔比星 Aclacinomycin A hydrochloride | 75443-99-1 | 10mg | 4800元 |
常見(jiàn)問(wèn)題列表
20S proteasome.
Topoisomerase I and II.
Aclacinomycin A could efficiently enter living cells and emit fluorescence
in situ
. Aclacinomycin A (10 μM for 15 min) is sufficient for clear detection of fluorescence in most of the cultured cells. Aclacinomycin A treatment (10 μM Acla for 15 min) results in approximately 20% dead (or nearly dead) cells.
Aclacinomycin A (Aclarubicin) effectively induces incorporation of exon 7 into SMN2 transcripts from the endogenous gene in type I SMA fibroblasts as well as into transcripts from a SMN2 minigene in the motor neuron cell line NSC34 .
Aclacinomycin A is very well absorbed in mice, rats, and dogs after its oral administration. The oral LD
50
(76.5 mg/kg) is about twice the iv LD
50
(35.6 mg/kg) in mice
[4
.
Aclacinomycin A (0.75-6 mg/kg, ip daily) dose-dependently exhibits tumor growth in mice-based Leukemia P-388 model
[4
.
| Animal Model: | DBA/2, CDF 1 (BALB/c×DBA/2) mice with Leukemia P-388 [4 . |
| Dosage: | 0.75 mg/kg, 1.5 mg/kg, 3 mg/kg, 6 mg/kg. |
| Administration: | Intraperitoneal administration daily for 10 days starting 3 hr after transplantation. |
| Result: | Inhibited tumor growth. |